ARTICLE: Detection and localization of surgically resectable cancers with a multi-analyte blood test

AUTHORS: Joshua D. CohenLu LiYuxuan WangChristopher ThoburnBahman AfsariLudmila DanilovaChristopher DouvilleAmmar A. JavedFay WongAustin MattoxRalph H. Hruban, Christopher L. Wolfgang, Michael G. Goggins, Marco Dal MolinTian-Li WangRichard RodenAlison P. KleinJanine PtakLisa DobbynJoy SchaeferNatalie SillimanMaria PopoliJoshua T. VogelsteinJames D. Browne, Robert E. SchoenRandall E. BrandJeanne TiePeter GibbsHui-Li WongAaron S. MansfieldJin JenSamir M. HanashMassimo FalconiPeter J. AllenShibin ZhouChetan BettegowdaLuis A. Diaz Jr.Cristian TomasettiKenneth W. KinzlerBert VogelsteinAnne Marie LennonNickolas Papadopoulos

JOURNAL: Science. 2018 Feb 23;359(6378):926-930. doi: 10.1126/science.aar3247. Epub 2018 Jan 18.

Abstract

Earlier detection is key to reducing cancer deaths. Here, we describe a blood test that can detect eight common cancer types through assessment of the levels of circulating proteins and mutations in cell-free DNA. We applied this test, called CancerSEEK, to 1005 patients with nonmetastatic, clinically detected cancers of the ovary, liver, stomach, pancreas, esophagus, colorectum, lung, or breast. CancerSEEK tests were positive in a median of 70% of the eight cancer types. The sensitivities ranged from 69 to 98% for the detection of five cancer types (ovary, liver, stomach, pancreas, and esophagus) for which there are no screening tests available for average-risk individuals. The specificity of CancerSEEK was greater than 99%: only 7 of 812 healthy controls scored positive. In addition, CancerSEEK localized the cancer to a small number of anatomic sites in a median of 83% of the patients.

For a link to the full article, click here: http://science.sciencemag.org/content/359/6378/926.long

Link to abstract online: https://www.ncbi.nlm.nih.gov/pubmed/29348365

Share This Post